Usage Examples
- The indication falls in the mandatory Annex scope, so EMA's centralised procedure is the only route to the EU market.
- We rebuilt the dossier to EU M1 v3.1.1 because EMA stopped accepting the older specification on 1 December 2025.
- CHMP opinion is forecast for Q3; budget another 67 days for the Commission decision before you set a launch date.
What is EMA (European Medicines Agency)?
EMA is the European Union agency that scientifically evaluates medicines submitted through the centralised procedure and monitors their safety, issuing recommendations on which the European Commission bases legally binding EU-wide authorisation decisions.
EMA exists because a company selling a medicine across Europe would otherwise have to prove the same science separately to every national authority. Operating since 1995 and now grounded in Regulation (EC) No 726/2004, EMA pools scientific experts drawn from the 27 EU Member States plus Iceland, Norway and Liechtenstein into a single assessment that serves the whole internal market.
EMA covers medicines evaluated through the centralised procedure, which is compulsory for biotechnology-derived products, advanced therapies, orphan medicines and new active substances in named disease areas, and optional for some others. EMA does not issue marketing authorisations, does not authorise clinical trials, and does not regulate medical devices, food supplements, cosmetics, price or reimbursement. Most medicines available in the EU are authorised nationally, not by EMA.
EMA is encountered in practice as a fixed timetable rather than an institution. EMA's CHMP evaluates the application over up to 210 active days, with PRAC input on the risk-management plan and CAT involvement for advanced therapies, then adopts an opinion. The European Commission converts that opinion into a binding authorisation within 67 days, valid across all EU Member States and in Iceland, Liechtenstein and Norway.
Not to be confused with
- European Commission
- the European Commission, not EMA, is the authorising body: it grants, suspends and revokes centralised marketing authorisations. EMA produces the science and the recommendation; the Commission produces the legal act.
- FDA
- FDA both assesses and approves for one country. EMA assesses for 30 countries and approves for none, because the approval power sits with the European Commission.
- MAA
- an MAA is the dossier a company files; EMA is the body that evaluates it. You submit an MAA to EMA, you do not submit an EMA.
- ICH
- ICH writes harmonised technical guidelines with no legal force of its own. EMA is a regulator that adopts ICH guidelines into the EU framework and assesses dossiers against them.
Working with EMA is procedural before it is scientific. These are the obligations that decide whether a dossier is even assessable.
What you must do
- 1Screen the product against Article 3 and the Annex before choosing a route; a product listed there cannot be placed on the EU market under a national, mutual-recognition or decentralised authorisationRegulation (EC) No 726/2004, Article 3 and Annex
- 2File one marketing authorisation application to EMA for the centralised route and plan the launch around the European Commission decision, issued within 67 days of the EMA recommendation, not around the CHMP opinion dateCentralised procedure - European Commission decision within 67 days
- 3Resource the assessment for up to 210 active days of CHMP evaluation, with PRAC input on the risk-management plan and CAT involvement for advanced-therapy medicinesCentralised procedure evaluation - 210 active days
- 4Build and validate the dossier in eCTD against the current EU Module 1 specification; since 1 December 2025 EMA accepts only eCTDs compliant with EU M1 v3.1.1 and validation criteria v8.2EU eCTD Module 1 v3.1.1 and validation criteria v8.2
- 5Submit the renewal application to EMA at the latest 9 months before the authorisation expires, and diarise that date at the time of grant rather than in year fiveRenewal of a centralised marketing authorisation
Common mistakes
Treating a CHMP positive opinion as the approval
Under EU law EMA has no authority to permit marketing. The European Commission issues the binding decision within 67 days of receiving EMA's recommendation, so launch, pricing and supply plans keyed to the opinion date are systematically about two months early.
Running a national, MRP or decentralised procedure for a product in the mandatory scope
Article 3 of Regulation (EC) No 726/2004 bars any product appearing in the Annex from the EU market without a centralised authorisation. Teams that discover this mid-procedure lose the elapsed assessment time and restart at EMA from day zero.
Building the dossier to a retired EU Module 1 specification
EMA has accepted only eCTDs compliant with EU M1 v3.1.1 and validation criteria v8.2 since 1 December 2025; v3.1 and criteria v8.1 were usable only until 30 November 2025. A dossier built to the old specification fails technical validation before any scientific assessment starts, and the clock does not begin until it passes.
When This Matters
- The indication falls in the mandatory Annex scope, so EMA's centralised procedure is the only route to the EU market.
- We rebuilt the dossier to EU M1 v3.1.1 because EMA stopped accepting the older specification on 1 December 2025.
- CHMP opinion is forecast for Q3; budget another 67 days for the Commission decision before you set a launch date.
Frequently Asked Questions
EMA evaluates medicines for the whole EU through a single application but cannot authorise them; the European Commission issues the legally binding decision within 67 days of the CHMP opinion. FDA both reviews and approves for the United States alone. An EMA authorisation also covers Iceland, Liechtenstein and Norway.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
